The European Union may need to reduce natural gas demand by 7% this winter, as low gas storage and the Russian LNG ban increase pressure.

According to Zhitong Finance APP, TRex Bio Inc., an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised 116.7 million dollars through its IPO, pricing at the lower end of its indicated range.

(1) The head of the European Banking Authority (EBA) stated that European banking regulators are conducting additional reviews regarding the risks associated with the trillions of euros in sovereign bond portfolios held by banks. (2) According to the official, as the yields on government bonds in some core European countries have soared to multi-year highs, the government debt investment portfolios held by banks require enhanced monitoring. (3) Currently, the relevant risk exposures still appear to be "within controllable ranges." (4) The net interest income generated from bonds has largely offset the impact of declining bond prices on the economic value of banks' equity. (5) He said, "So far, we have not seen banks suffer significant losses as a result of the current situation, and we are confident that regulators are taking the necessary responsive measures."

According to Jinse Finance, it has been reported that Iambic Therapeutics (IAM.US), a biotechnology company developing small-molecule anti-cancer therapies based on its self-developed artificial intelligence (AI) platform and currently in Phase I clinical trials, announced its IPO terms on Thursday. The San Diego, California-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 per share. Some investors have already expressed their intention to purchase $60 million worth of shares in this offering, accounting for 40% of the deal. At the midpoint of the proposed price range, Iambic Therapeutics would have a fully diluted market value of $809 million.

According to information from Zhitong Finance APP, Amaero (AMRO.US), a producer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has resumed its initial public offering (IPO) plans in the United States as of Thursday, submitting new documents to the U.S. Securities and Exchange Commission (SEC) revealing a reduced offering size. The company is currently listed on the Australian Securities Exchange and had previously attempted a cross-listing on Nasdaq in September, but postponed the listing due to unfavorable market conditions. The exact timing of the IPO remains undetermined.